Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Cystic Fibrosis · Hepatitis C

Vertex Pharmaceuticals (Australia)

Vertex Pharmaceuticals (Australia) Pty.

Vertex Pharmaceuticals (Australia) drug portfolio — 64 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US HQ
1989 Founded
6,304 Employees
TGA registrant Type
Company details
Status
Public
HQ
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US
Founded
1989
Employees
6,304
Programs
159
Drugs
64
Patents
991
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Drug Pipeline

Vertex Pharmaceuticals (Australia) pipeline

Portfolio lens on 64 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Vertex Pharmaceuticals (Australia) drug portfolio — 64 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

64 compounds

  2. acrivastine

    US regulatory status: approved. Molecular target: Histamine H1 receptor.

    Target
    Histamine H1 receptor
    Mechanism
    Histamine H1 receptor antagonist

  3. adalimumab-adbm

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  4. administration

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  6. anti-

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  7. asenapine maleate

    US regulatory status: approved. Molecular target: D(2) dopamine receptor.

    Target
    D(2) dopamine receptor
    Mechanism
    Dopamine D2 receptor antagonist

  8. aspirin

    US regulatory status: approved. Molecular target: Cyclooxygenase.

    Target
    Cyclooxygenase
    Mechanism
    Cyclooxygenase inhibitor

  9. biological

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  10. busulfan

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  11. calcium chloride

    US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.

    Mechanism
    Dihydrofolate reductase inhibitor

  12. capsule

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  13. capsules

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  14. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  15. cells

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  16. combination

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  17. deutivacaftor

    US regulatory status: approved. Molecular target: Cystic fibrosis transmembrane conductance regulator.

    Target
    Cystic fibrosis transmembrane conductance regulator
    Mechanism
    Cystic fibrosis transmembrane conductance regulator activator

  19. doxorubicin

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Vertex Pharmaceuticals (Australia)'s portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.

    Mechanism
    DNA topoisomerase II alpha inhibitor

  21. exagamglogene autotemcel

    Blood and blood forming organs (B06)

    Blood and blood forming organs (B06) compound in Vertex Pharmaceuticals (Australia)'s portfolio. Molecular target: BCL11 transcription factor A.

    Target
    BCL11 transcription factor A
    Mechanism
    B-cell lymphoma/leukemia 11A gene editing negative modulator

  22. filgrastim

    Antineoplastic and immunomodulating agents (L03)

    US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.

    Target
    Granulocyte colony-stimulating factor receptor
    Mechanism
    Granulocyte colony stimulating factor receptor agonist

  23. formulation

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  24. granule

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  25. granules

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  26. hema-

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  28. infusion

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  29. injection

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  30. interferon alfa-2a

    Antineoplastic and immunomodulating agents (L03)

    Antineoplastic and immunomodulating agents (L03) compound in Vertex Pharmaceuticals (Australia)'s portfolio. Molecular target: Interferon alpha/beta receptor.

    Target
    Interferon alpha/beta receptor
    Mechanism
    Interferon alpha/beta receptor agonist

  31. ivacaftor

    Respiratory system (R07)

    US regulatory status: approved. Molecular target: Cystic fibrosis transmembrane conductance regulator.

    Target
    Cystic fibrosis transmembrane conductance regulator
    Mechanism
    Cystic fibrosis transmembrane conductance regulator positive modulator

  32. lumacaftor

    Respiratory system (R07)

    Respiratory system (R07) compound in Vertex Pharmaceuticals (Australia)'s portfolio. Molecular target: Cystic fibrosis transmembrane conductance regulator.

    Target
    Cystic fibrosis transmembrane conductance regulator
    Mechanism
    Cystic fibrosis transmembrane conductance regulator stabiliser

  33. lumacaftor + ivacaftor

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  34. matching

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  35. moxifloxacin

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  36. null

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  37. peginterferon

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  38. peginterferon alfa-2a

    Antineoplastic and immunomodulating agents (L03)

    US regulatory status: approved. Molecular target: Interferon alpha/beta receptor.

    Target
    Interferon alpha/beta receptor
    Mechanism
    Interferon alpha/beta receptor agonist

  39. penicillamine

    US regulatory status: approved. Molecular target: Copper.

    Target
    Copper
    Mechanism
    Copper chelating agent

  41. placebo

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  42. plerixafor

    Antineoplastic and immunomodulating agents (L03)

    US regulatory status: approved. Molecular target: C-X-C chemokine receptor type 4.

    Target
    C-X-C chemokine receptor type 4
    Mechanism
    C-X-C chemokine receptor type 4 partial agonist

  43. postoperative

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  44. prednisone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  45. pregabalin

    Nervous system (N02)

    US regulatory status: approved. Molecular target: Voltage-gated calcium channel.

    Target
    Voltage-gated calcium channel
    Mechanism
    Voltage-gated calcium channel modulator

  46. ribavirin

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: Inosine-5'-monophosphate dehydrogenase 1.

    Target
    Inosine-5'-monophosphate dehydrogenase 1
    Mechanism
    Inosine-5'-monophosphate dehydrogenase 1 inhibitor

  47. saline

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  48. sequence

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  50. sofosbuvir

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: RNA-directed RNA polymerase.

    Target
    RNA-directed RNA polymerase
    Mechanism
    RNA-directed RNA polymerase inhibitor

  51. solution

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  52. standard

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  53. stro-

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  54. suspension

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  56. tablet

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  57. tablets

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  58. tacrolimus

    Dermatologicals (D11)

    US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.

    Target
    Peptidyl-prolyl cis-trans isomerase FKBP1A
    Mechanism
    FK506-binding protein 1A inhibitor

  60. telaprevir

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: Hepatitis C virus serine protease, NS3/NS4A.

    Target
    Hepatitis C virus serine protease, NS3/NS4A
    Mechanism
    Hepatitis C virus serine protease, NS3/NS4A inhibitor

  61. tezacaftor

    Respiratory system (R07)

    Respiratory system (R07) compound in Vertex Pharmaceuticals (Australia)'s portfolio. Molecular target: Cystic fibrosis transmembrane conductance regulator.

    Target
    Cystic fibrosis transmembrane conductance regulator
    Mechanism
    Cystic fibrosis transmembrane conductance regulator positive modulator

  62. therapy

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  63. treatment

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

  64. vaccine

    Development asset linked to Vertex Pharmaceuticals (Australia) in public FDA and regional records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.